research use only

Alogliptin (SYR-322) benzoate DPP inhibitor

Name: Alogliptin (SYR-322) benzoate
Brand: Selleck Chemicals
SKU: S2868
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S2868

Alogliptin (SYR-322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.

Alogliptin (SYR-322) benzoate DPP inhibitor Chemical Structure

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease Tyrosinase HIV Protease Serine Protease
Other DPP Inhibitors	Talabostat (Val-boroPro, PT-100) Mesylate Puromycin aminonucleoside MK-3102 (Omarigliptin) Brensocatib Lobeliae Chinensis Extract Teneligliptin Hydrobromide Hydrate Anagliptin Trelagliptin Teneligliptin hydrobromide Trelagliptin succinate

Solubility

In vitro
Batch:

DMSO : 68 mg/mL (147.34 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 2 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	0.5% methylcellulose Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (21.67mM)	Taking the 1 mL working solution as an example, take 10 mg of this product, add it to 1 ml of 0.5% methylcellulose clear solution, and mix evenly to form a uniform suspension. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	461.51	Formula	C₁₈H₂₁N₅O₂.C₇H₆O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	850649-62-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	SYR-322			SMILES	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.C1=CC=C(C=C1)C(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	DPP-4 <10 nM
In vitro	Alogliptin(SYR-322) is a potent inhibitor of DPP-4 and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9. Alogliptin is not an inhibitor of CYP-450 enzymes and does not block the hERG channel at concentrations up to 30 μM.
In vivo	Alogliptin(SYR-322) produces dose-dependent improvements in glucose tolerance and increases plasma insulin levels in female Wistar fatty rats. Acute administration of alogliptin results in a significant decrease in plasma DPP-4 activity, and increases plasma active GLP-1. Alogliptin improves glucose tolerance at a dose of 0.3 mg/kg and higher, with a dose-dependent increase in plasma IRI, suggesting that improved glucose tolerance results from the ability of alogliptin to enhance insulin secretion.
References	[1] https://pubmed.ncbi.nlm.nih.gov/17441705/ [2] https://pubmed.ncbi.nlm.nih.gov/19427871/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07289750	NOT_YET_RECRUITING	T2DM; MAFLD	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	2026-05-01	PHASE4
NCT07093476	RECRUITING	T2DM; Diabete Type 2; DM	Celltrion	2025-07-18	PHASE3
NCT03499704	COMPLETED	Diabetes Mellitus, Type 2	Celltrion Pharm, Inc.	2020-02-11	PHASE4
NCT05363592	COMPLETED	Healthy	Celltrion	2022-06-25	PHASE1
NCT05363384	COMPLETED	Healthy	Celltrion	2022-06-11	PHASE1
NCT05782192	COMPLETED	Diabetes Mellitus, Type 2	Shenzhen Salubris Pharmaceuticals Co., Ltd.	2019-06-13	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):